FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1536174937> ?p ?o ?g. }

• W1536174937 endingPage "S39" @default.
• W1536174937 startingPage "S37" @default.
• W1536174937 abstract "This is a report of 148 patients with hematologic malignancies who received an unmanipulated haploidentical bone marrow transplant (BMT), followed by post-transplant high-dose cyclophosphamide (PT-CY). All patients received a myeloablative conditioning consisting of thiotepa, busulfan, fludarabine (n=92) or TBI, fludarabine (n=56). The median age was 47 years (17-74); 47 patients were in first remission (CR1), 37 in second remission (CR2) and 64 had an active disease; all patients were first grafts. The diagnosis was acute leukemia (n=75), myelodisplastic syndrome (n=24), myelofibrosis (n=16), high-grade lymphoma (n=15) and others (n=18). GVHD prophylaxis consisted in PT-CY on days +3 and +5, cyclosporine (from day 0), and mycophenolate (from day +1). The median day for neutrophil engraftment was day +18 (13-32). The cumulative incidence of grades II-IV acute GVHD was 24%, and of grades III-IV GVHD 10%. The incidence of moderate-severe chronic GVHD was 12%. With a median follow-up for the surviving patients of 313 days (100-1162), the cumulative incidence of transplant-related mortality (TRM) is 13%, and the relapse-related death is 23%. The actuarial 22 months overall survival is 77% for CR1 patients, 49% for CR2 patients and 38% for patients grafted in relapse (P<0.001). Major causes of death were relapse (22%), GVHD (2%) and infections (6%). We confirm our initial results, suggesting that a myeloablative conditioning regimen followed by unmanipulated haploidentical BMT with PT-CY, results in a low risk of acute and chronic GVHD and encouraging rates of TRM and overall survival, also for patients with active disease at the time of transplant." @default.
• W1536174937 created "2016-06-24" @default.
• W1536174937 creator A5003135516 @default.
• W1536174937 creator A5010254709 @default.
• W1536174937 creator A5018395647 @default.
• W1536174937 creator A5022984958 @default.
• W1536174937 creator A5025804554 @default.
• W1536174937 creator A5026031351 @default.
• W1536174937 creator A5029072398 @default.
• W1536174937 creator A5033482554 @default.
• W1536174937 creator A5039434552 @default.
• W1536174937 creator A5042348175 @default.
• W1536174937 creator A5050112289 @default.
• W1536174937 creator A5066888430 @default.
• W1536174937 creator A5069969800 @default.
• W1536174937 creator A5072862786 @default.
• W1536174937 creator A5080844744 @default.
• W1536174937 creator A5083379505 @default.
• W1536174937 date "2015-06-01" @default.
• W1536174937 modified "2023-10-10" @default.
• W1536174937 title "Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update" @default.
• W1536174937 cites W2029070864 @default.
• W1536174937 cites W2039334806 @default.
• W1536174937 cites W2044467556 @default.
• W1536174937 cites W2061878111 @default.
• W1536174937 cites W2130040182 @default.
• W1536174937 cites W2141696179 @default.
• W1536174937 cites W2148549851 @default.
• W1536174937 cites W2149502955 @default.
• W1536174937 cites W2317548431 @default.
• W1536174937 doi "https://doi.org/10.1038/bmt.2015.93" @default.
• W1536174937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26039205" @default.
• W1536174937 hasPublicationYear "2015" @default.
• W1536174937 type Work @default.
• W1536174937 sameAs 1536174937 @default.
• W1536174937 citedByCount "134" @default.
• W1536174937 countsByYear W15361749372015 @default.
• W1536174937 countsByYear W15361749372016 @default.
• W1536174937 countsByYear W15361749372017 @default.
• W1536174937 countsByYear W15361749372018 @default.
• W1536174937 countsByYear W15361749372019 @default.
• W1536174937 countsByYear W15361749372020 @default.
• W1536174937 countsByYear W15361749372021 @default.
• W1536174937 countsByYear W15361749372022 @default.
• W1536174937 countsByYear W15361749372023 @default.
• W1536174937 crossrefType "journal-article" @default.
• W1536174937 hasAuthorship W1536174937A5003135516 @default.
• W1536174937 hasAuthorship W1536174937A5010254709 @default.
• W1536174937 hasAuthorship W1536174937A5018395647 @default.
• W1536174937 hasAuthorship W1536174937A5022984958 @default.
• W1536174937 hasAuthorship W1536174937A5025804554 @default.
• W1536174937 hasAuthorship W1536174937A5026031351 @default.
• W1536174937 hasAuthorship W1536174937A5029072398 @default.
• W1536174937 hasAuthorship W1536174937A5033482554 @default.
• W1536174937 hasAuthorship W1536174937A5039434552 @default.
• W1536174937 hasAuthorship W1536174937A5042348175 @default.
• W1536174937 hasAuthorship W1536174937A5050112289 @default.
• W1536174937 hasAuthorship W1536174937A5066888430 @default.
• W1536174937 hasAuthorship W1536174937A5069969800 @default.
• W1536174937 hasAuthorship W1536174937A5072862786 @default.
• W1536174937 hasAuthorship W1536174937A5080844744 @default.
• W1536174937 hasAuthorship W1536174937A5083379505 @default.
• W1536174937 hasBestOaLocation W15361749371 @default.
• W1536174937 hasConcept C120665830 @default.
• W1536174937 hasConcept C121332964 @default.
• W1536174937 hasConcept C126322002 @default.
• W1536174937 hasConcept C141071460 @default.
• W1536174937 hasConcept C2776694085 @default.
• W1536174937 hasConcept C2776755627 @default.
• W1536174937 hasConcept C2778880498 @default.
• W1536174937 hasConcept C2779263901 @default.
• W1536174937 hasConcept C2779968505 @default.
• W1536174937 hasConcept C2780611847 @default.
• W1536174937 hasConcept C2911091166 @default.
• W1536174937 hasConcept C61511704 @default.
• W1536174937 hasConcept C71924100 @default.
• W1536174937 hasConcept C88879693 @default.
• W1536174937 hasConcept C90924648 @default.
• W1536174937 hasConceptScore W1536174937C120665830 @default.
• W1536174937 hasConceptScore W1536174937C121332964 @default.
• W1536174937 hasConceptScore W1536174937C126322002 @default.
• W1536174937 hasConceptScore W1536174937C141071460 @default.
• W1536174937 hasConceptScore W1536174937C2776694085 @default.
• W1536174937 hasConceptScore W1536174937C2776755627 @default.
• W1536174937 hasConceptScore W1536174937C2778880498 @default.
• W1536174937 hasConceptScore W1536174937C2779263901 @default.
• W1536174937 hasConceptScore W1536174937C2779968505 @default.
• W1536174937 hasConceptScore W1536174937C2780611847 @default.
• W1536174937 hasConceptScore W1536174937C2911091166 @default.
• W1536174937 hasConceptScore W1536174937C61511704 @default.
• W1536174937 hasConceptScore W1536174937C71924100 @default.
• W1536174937 hasConceptScore W1536174937C88879693 @default.
• W1536174937 hasConceptScore W1536174937C90924648 @default.
• W1536174937 hasIssue "S2" @default.
• W1536174937 hasLocation W15361749371 @default.
• W1536174937 hasLocation W15361749372 @default.
• W1536174937 hasOpenAccess W1536174937 @default.
• W1536174937 hasPrimaryLocation W15361749371 @default.

• next